drugset
drugset / Trial / NCT07139470

Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer

NCT07139470 ↗

Phase 1/2 Not yet recruiting 59 enrolled Tianjin Medical University Cancer Institute and Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, single-arm, multicenter phase I/II study to evaluate the safety and efficacy of sac-TMT plus anlotinib in previously treated mTNBC. The study is expected to enroll up to 59 eligible patients.

Timeline

Start
2025-08-15
Primary completion
2027-04-15
Completion
2027-10-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Catequentinib Small molecule 8 mg —
Subject Catequentinib Small molecule 10 mg —
Subject Catequentinib Small molecule 12 mg —
Subject Sacituzumab Tirumotecan Other / unclassified 4 mg/kg —

Indications

triple-negative breast carcinoma